This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Agilent Technologies, Inc., Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC. Active years: 2020-2026.
Company Filing History:
3 out of 4,730 
2 out of 2,405 
1 out of 67 Years Active: 2020-2026
Title: Stephanie Waldroup: Innovator in Anti-PD Therapy
Introduction
Stephanie Waldroup is a prominent inventor based in Santa Barbara, CA (US). She has made significant contributions to the field of medical therapies, particularly in the area of anti-PD treatments. With a total of 3 patents, her work focuses on improving the eligibility criteria for patients undergoing such therapies.
Latest Patents
Waldroup's latest patents include innovative methods for determining the eligibility of subjects with malignancies for treatment with anti-PD therapeutic agents. One of her notable patents outlines scoring methods based on a Combined Positive Score (CPS) derived from tumor tissue samples. This advancement not only enhances the selection process for patients but also includes compositions and kits for performing these methods.
Career Highlights
Throughout her career, Stephanie has worked with leading companies in the pharmaceutical and biotechnology sectors. Notable organizations include Agilent Technologies, Inc. and Merck Sharp & Dohme Corp. Her experience in these companies has allowed her to develop and refine her innovative approaches to cancer treatment.
Collaborations
Waldroup has collaborated with esteemed colleagues such as David Stanforth and Kenneth Emancipator. These partnerships have contributed to her success and the advancement of her research in anti-PD therapies.
Conclusion
Stephanie Waldroup is a trailblazer in the field of anti-PD therapy, with a focus on improving patient eligibility through innovative scoring methods. Her contributions are paving the way for more effective cancer treatments and enhancing the lives of many patients.